Welcome to our dedicated page for Neuphoria Therapeutics news (Ticker: NEUP), a resource for investors and traders seeking the latest updates and insights on Neuphoria Therapeutics stock.
Neuphoria Therapeutics Inc. (Nasdaq: NEUP) is a clinical-stage biotechnology company focused on therapies for neuropsychiatric and central nervous system disorders, and its news flow reflects both scientific progress and corporate developments. Company announcements emphasize the development of BNC210, an oral, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, and its role in anxiety-related indications such as social anxiety disorder and post-traumatic stress disorder.
News coverage for NEUP frequently includes clinical trial updates, such as milestones and outcomes from the AFFIRM-1 Phase 3 trial in social anxiety disorder and earlier studies across anxiety indications. Releases have detailed when target enrollment was reached, when last patient last visit milestones were achieved, and how topline data affected Neuphoria’s decisions about continuing or halting specific programs.
Investors following NEUP news will also see strategic and corporate actions highlighted. The company has announced a comprehensive strategic review to evaluate options including mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions. Related news items describe the engagement of H.C. Wainwright & Co. as financial advisor, the adoption of a limited-duration stockholder rights plan, and communications around an unsolicited indication of interest and proxy contest initiated by Lynx1 Master Fund LP.
Another important category of NEUP news involves partnership and pipeline disclosures. Neuphoria regularly references its strategic collaboration with Merck & Co., Inc. on positive allosteric modulator candidates for cognitive deficits in Alzheimer’s disease and other CNS conditions, including Merck-led Phase 2 work on MK-1167. Updates may also touch on preclinical programs, such as next-generation α7 nicotinic acetylcholine receptor and Kv3.1/3.2 efforts in lead optimization.
For readers and investors, the NEUP news page offers a single location to review clinical data announcements, strategic review updates, proxy and governance communications, and partnership-related developments. Regular visits can help track how Neuphoria’s pipeline, corporate strategy, and shareholder dynamics evolve over time based on official company statements.
Neuphoria Therapeutics (NASDAQ: NEUP) provided Q1 2025 business updates, highlighting progress in its neuropsychiatric drug development pipeline. The company's lead program, BNC210, is advancing in the Phase 3 AFFIRM-1 trial for Social Anxiety Disorder (SAD), with topline results expected in Q3 2025. BNC210 has shown promising results in previous trials, demonstrating rapid-onset anti-anxiety effects without sedation or addiction risks.
The company is also planning a Phase 2b SYMPHONY trial for BNC210 in PTSD following a successful FDA End-of-Phase 2 meeting. Additionally, Neuphoria's partnered asset MK-1167, an α7 nicotinic acetylcholine receptor PAM, is progressing in a Merck-led Phase 2 trial for Alzheimer's disease. The company maintains a cash runway extending into Q3 2026.
Neuphoria Therapeutics (NASDAQ: NEUP) has provided an update on its 2024 achievements and 2025 plans. The company reached significant milestones in its clinical programs, including:
The advancement of BNC210 to Phase 3 AFFIRM-1 trial for Social Anxiety Disorder (SAD), with topline results expected in Q3 2025. Additionally, Merck initiated a Phase 2 trial of MK-1167 for Alzheimer's disease treatment.
Key financial developments include receiving a US$15M milestone payment from Merck in March 2025, extending cash runway to Q3 2026. The company is eligible for up to $450M in additional milestone payments plus royalties from Merck, and AUS$117M from Carina Biotech for their partnered programs.
For 2025, Neuphoria plans to initiate a Phase 2b dose-ranging study of BNC210 in PTSD in Q4, following the SAD trial results. The company successfully re-domiciled from Australia to the United States in December 2024.
Neuphoria Therapeutics (Nasdaq: NEUP), a clinical-stage biotechnology company focused on neuropsychiatric disorder treatments, announced it will ring the Nasdaq Opening Bell on March 3rd, 2025, at the Nasdaq MarketSite in Times Square, New York City.
The ceremony will be led by President and CEO Spyros Papapetropoulos MD, PhD, accompanied by the company's board of directors, management team, and advisors. The event celebrates Neuphoria's successful redomiciliation to the US and the launch of Neuphoria Therapeutics. The live broadcast will begin at 9:15 a.m. Eastern Time.
Neuphoria Therapeutics (Nasdaq: NEUP) announced it will receive a $15 million milestone payment from Merck following the initiation of a Phase 2 clinical trial for MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator, in Alzheimer's disease dementia.
This marks the second milestone achieved in the Merck collaboration. Under the agreement, Neuphoria remains eligible for up to $450 million in additional milestone payments for development and commercial achievements, plus royalties on net sales of licensed medicines.
The Phase 2 trial (NCT06721156) will evaluate MK-1167's safety and efficacy in treating Alzheimer's disease symptoms. The milestone achievement validates Neuphoria's ion channel targeting platform, which has produced several clinical and preclinical stage drug candidates.
Neuphoria Therapeutics (Nasdaq: NEUP) has completed its re-domiciliation from Australia to the United States, transforming from Bionomics The company's shares will begin trading on Nasdaq under the symbol 'NEUP' starting December 24, 2024. As part of the transition, Neuphoria will issue new stock options to existing Bionomics option holders and a warrant to purchase 1,054,381 shares to an institutional investor who previously held warrants for 12,652,572 Bionomics American Depositary Shares (ADSs).